Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Latest Pharmaceuticals and Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc. Stock News

As of July 31, 2026, Crinetics Pharmaceuticals, Inc. had a $8.8 billion market capitalization, compared to the Pharmaceuticals median of $579.1 million. Crinetics Pharmaceuticals, Inc.’s stock is up 79.4% in 2026, down 0.3% in the previous five trading days and up 185.73% in the past year.

Currently, Crinetics Pharmaceuticals, Inc. does not have a price-earnings ratio. Crinetics Pharmaceuticals, Inc.’s trailing 12-month revenue is $18.1 million with a % net profit margin. As of July 31, 2026, Crinetics Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.621 per share for the current fiscal year. Crinetics Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 31, 2026, Supernus Pharmaceuticals, Inc. had a $2.6 billion market cap, putting it in the 57th percentile of all stocks. Supernus Pharmaceuticals, Inc.’s stock is down 10.2% in 2026, down 3.4% in the previous five trading days and up 32.99% in the past year.

Currently, Supernus Pharmaceuticals, Inc. does not have a price-earnings ratio. Supernus Pharmaceuticals, Inc.’s trailing 12-month revenue is $776.8 million with a -3.7% net profit margin. Year-over-year quarterly sales growth most recently was 38.7%. Analysts expect adjusted earnings to reach $2.487 per share for the current fiscal year. Supernus Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Crinetics Pharmaceuticals, Inc.	CRNX	F
Supernus Pharmaceuticals, Inc.	SUPN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Crinetics Pharmaceuticals, Inc. has a Value Score of 3, which is Ultra Expensive. Supernus Pharmaceuticals, Inc. has a Value Score of 25, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals or Inc. is the better investment when it comes to value.

Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Crinetics Pharmaceuticals, Inc.	CRNX	D
Supernus Pharmaceuticals, Inc.	SUPN	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Crinetics Pharmaceuticals, Inc. has a Quality Score of 26, which is Weak. Supernus Pharmaceuticals, Inc. has a Quality Score of 46, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals or Inc. is the better investment when it comes to quality.

Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Crinetics Pharmaceuticals, Inc.	CRNX	A
Supernus Pharmaceuticals, Inc.	SUPN	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Crinetics Pharmaceuticals, Inc. has a Momentum Score of 98, which is Very Strong. Supernus Pharmaceuticals, Inc. has a Momentum Score of 58, which is Average.

The Momentum Grade Winner: Crinetics Pharmaceuticals, Inc.

As you can clearly see from the Momentum Grade breakdown above, Crinetics Pharmaceuticals, Inc. is considered to have stronger momentum compared to Supernus Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Crinetics Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc. Grades

In addition to Quality, Momentum and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals or Inc. Stock?

Overall, Crinetics Pharmaceuticals, Inc. stock has a Value Score of 3, Momentum Score of 98 and Quality Score of 26.

Supernus Pharmaceuticals, Inc. stock has a Value Score of 25, Momentum Score of 58 and Quality Score of 46.

Comparing Crinetics Pharmaceuticals, Inc., Supernus Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.